Conversely, neither treatment with buffer nor with all concentrations tested (0.01 – 100 ng/ml) of rLifADTD-AAA impaired the proliferation of CD4+ and CD8+ T cells (Figures 1, 2B). The gene discussed is CD8A; the disease is triple-A syndrome.